Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...

retriever generates disease-specific transcriptional drug response signatures by merging transcriptional signatures over time, concentration, and cell-type. These signatures can then be matched to ...

On the other hand, mechanisms of acquired resistance to 'pathway-targeted' drugs, such as the various clinically active kinase inhibitors, have been somewhat more straightforward to elucidate and ...

MLN0128 (formerly known as INK128) is a novel, orally active mTOR kinase inhibitor currently in clinical development. Here, we evaluated MLN0128 in preclinical models of B-cell acute lymphoblastic ...

Unique Pharmacological Profile: In biochemical and cellular assays, ATI-2138 demonstrated a similar high potency for inhibiting both ITK and JAK3, compared to ritlecitinib which was markedly less ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

micro-RNA-mediated inhibition of p27 translation emerges as a novel mechanism that can reduce ... at Thr157 and Thr198 by members of the AGC kinase family promotes assembly of p27–cyclin D ...

DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report ... combination of PB and TURSO and their complementary mechanisms of action will allow to synergistically target abnormal cell ...

Mode of Action Kinetic Analysis Kinase inhibitor drug discovery requires the optimization of several other drug-like properties such as cellular potency, pharmacokinetics and pharmacodynamics, and ...

Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel ...